Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition Oct 16 (Reuters) - Swiss drugmaker Novartis NOVN.S has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry.
The trial was evaluating whether the oral medication was safe and effective for treating lupus nephritis when added to standard medical care
Lupus nephritis is a severe inflammation of the kidneys caused by the autoimmune disease lupus
The government database, last updated on October 15, shows Novartis decided to conclude the study after completing the first part
It gives no other explanation and does not say whether safety or effectiveness played a role
Endpoints News reported the development earlier on Friday
Novartis did not immediately respond to a Reuters request for comment
The US FDA first approved Fabhalta in 2023 for a rare blood disorder called PNH. It has since been approved for two kidney diseases, IgA nephropathy and C3 glomerulopathy
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
((Kamal.Choudhury@thomsonreuters.com))
Recent news on Novartis AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Novartis Remibrutinib Delivered Comprehensive Disease Control In Phase III RMS Trials
Bristol Myers discloses patient death in early-stage cell therapy study (updated)
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview